
    
      Patients were randomized to receive CMAB819 or Nivolumab 480 mg by intravenous infusion every
      4 weeks until documented disease progression, discontinuation, withdrawal of consent, or up
      to 4 doses in subjects without disease progression, whichever occurs earlier. After
      completing 4 doses of therapy, administer of CMAB819 480 mg intravenous (IV) solution for
      injection every 4 weeks until documented disease progression, discontinuation, withdrawal of
      consent or the study ends. Randomization was stratified by Eastern Cooperative Oncology Group
      (ECOG) performance status ECOG (0 versus 1), sex (male versus female), weight （≤60 kg versus
      >60kg）and clinical trial institution (up to 20 centers) .
    
  